COLL - Collegium Pharmaceutical, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$58.00
DETAILS
HIGH:
$60.00
LOW:
$56.00
MEDIAN:
$58.00
CONSENSUS:
$58.00
UPSIDE:
70.24%
About Collegium Pharmaceutical, Inc. (https://www.collegiumpharma.com)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Vikram Karnani | President, Chief Executive Officer & Director | 1975 | $1,715,846 USD |
| Colleen Tupper | Executive Vice President & Chief Financial Officer | 1976 | $1,030,569 USD |
| Scott Dreyer | Executive Vice President & Chief Commercial Officer | 1972 | $880,739 USD |
| Thomas Smith FAAFP | Executive Vice President & Chief Medical Officer | 1961 | $825,694 USD |
| David Dieter | Executive Vice President, General Counsel & Corporate Secretary | 1964 | $782,283 USD |
| Dean J. Patras | Chief People Officer | – | – |
| Ian Karp | Head of Investor Relations | – | – |
| Jane Gonnerman | Executive Vice President of Strategy & Corporate Development | – | – |
| Jessica Cotrone | Senior Vice President of Communications & Corporate Affairs | – | – |
| Scott Sudduth | EVP & Head of Technical Operations | – | – |